<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03026881</url>
  </required_header>
  <id_info>
    <org_study_id>FZPL-I-103-GC</org_study_id>
    <nct_id>NCT03026881</nct_id>
  </id_info>
  <brief_title>A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients</brief_title>
  <official_title>An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib Given in Combination With Apatinib and Paclitaxel in the 2nd Line Treatment of Patients With Recurrent or Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Hospital of the Chinese Academy of Military Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor; Apatinib is an oral&#xD;
      selective VEGFR inhibitor. This open-label, dose finding phase I trial studies the&#xD;
      tolerability and the best dose of Fluzoparib in combination with apatinib and paclitaxel and&#xD;
      to see how well this three drugs work together in the treatment of patients with recurrent&#xD;
      and metastatic gastric cancer who progress following first-line therapy. The safety and&#xD;
      efficacy of fluzoparib in combination with apatinib and paclitaxel will be explored.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT and safety: Adverse Events (AEs), physical examination, vital signs including blood pressure (BP), pulse, electrocardiogram (ECG) and laboratory findings including clinical chemistry, hematology, urinalysis.</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>DLT and safety defined by CTC version 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best of ORR</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DOR)</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>From date of enrollment until the date of first objective progression, assessed up to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to 33 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half life (t1/2)</measure>
    <time_frame>Up to 33 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUCï¼‰</measure>
    <time_frame>Up to 33 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (V/F)</measure>
    <time_frame>Up to 33 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Clearance (CL/F)</measure>
    <time_frame>Up to 33 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Recurrent and Metastatic Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Fluzoparib + Apatinib + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib</intervention_name>
    <description>Fluzoparib either at 20,30,40mg twice daily,capsule oral.</description>
    <arm_group_label>Fluzoparib + Apatinib + Paclitaxel</arm_group_label>
    <other_name>SHR3162</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Oral</description>
    <arm_group_label>Fluzoparib + Apatinib + Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>Fluzoparib + Apatinib + Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG performance status of 0 to 1.&#xD;
&#xD;
          -  Life expectancy of more than 12 weeks.&#xD;
&#xD;
          -  Histologically or cytologically confirmed gastric adenocarcinoma( adenocarcinoma of&#xD;
             the gastroesophageal junction included).&#xD;
&#xD;
          -  Recurrent or metastatic gastric cancer that has progressed following first&#xD;
             line-therapy.&#xD;
&#xD;
          -  At least one lesion (measurable and/or non-measurable) that can be accurately assessed&#xD;
             by imaging (CT/MRI) at baseline&#xD;
&#xD;
          -  Subjects who have overall good overall general condition.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who received any previous treatment with any PARP inhibitors.&#xD;
&#xD;
          -  Subjects who received any previous treatment with any taxanes.&#xD;
&#xD;
          -  More than one prior chemotherapy regimen for the treatment of gastric cancer in the&#xD;
             metastatic or recurrent setting.&#xD;
&#xD;
          -  Less than 4 weeks from the last clinical trial.&#xD;
&#xD;
          -  Less than 2 weeks from the last radiotherapy, chemotherapy, surgery, hormone treatment&#xD;
             and target therapy.&#xD;
&#xD;
          -  Unstable hypertension.&#xD;
&#xD;
          -  Subjects that are unable to swallow, or dysfunction of gastrointestinal absorption.&#xD;
&#xD;
          -  Subjects with brain metastases.&#xD;
&#xD;
          -  Subjects with uncontrolled hypokalemia and hypomagnesemia before study entry.&#xD;
&#xD;
          -  Subjects with a known hypersensitivity to fluzoparib, apatinib, paclitaxel or any of&#xD;
             the excipients of the product.&#xD;
&#xD;
          -  Ongoing infection (determined by investigator).&#xD;
&#xD;
          -  History of immunodeficiency, including HIV-positive, suffering from other acquired,&#xD;
             congenital immunodeficiency disease, or history of organ transplantation.&#xD;
&#xD;
          -  Subjects who can not interrupt the using of the drugs that may cause QT prolongation&#xD;
             during study.&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianming Xu, MD</last_name>
    <email>jmxu2003@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Affiliated Hospital of Military Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianming Xu, MD</last_name>
      <email>jmxu2003@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>December 21, 2016</study_first_submitted>
  <study_first_submitted_qc>January 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2017</study_first_posted>
  <last_update_submitted>March 5, 2017</last_update_submitted>
  <last_update_submitted_qc>March 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PARP inhibitor</keyword>
  <keyword>VEGFR inhibitor</keyword>
  <keyword>Combination therapy</keyword>
  <keyword>Gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

